Black Friday Savings ! Exclusive Deals on Latest Pharma and Medical Technology Reports.

Explore Now

Bullous Pemphigoid Epidemiology Forecast

DelveInsight’s ‘Bullous Pemphigoid-Epidemiology Forecast–2030’ report deliver an in-depth understanding of the Bullous Pemphigoid historical and forecasted epidemiology trends in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan.

Geographies Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

Study Period: 2018–2030

Bullous Pemphigoid Understanding

Bullous Pemphigoid Overview

Bullous Pemphigoid (BP) is an acquired autoimmune subepidermal bullous disease in which autoantibodies are directed against the skin’s basement membrane zone components. Mainly IgG (rarely IgA, IgM, and IgE) autoantibodies bind to components of the hemidesmosome adhesion complex, the BP230, and BP180 antigens.


It is characterized by blistering, urticarial lesions (hives), and itching. Less commonly, these blisters can involve the mucous membranes, including the eyes, oral mucosa, esophagus, and genital mucosa. It typically presents in older adults as a generalized intensely itchy blistering skin condition.


Bullous Pemphigoid Diagnosis

The initial evaluation of a patient with bullous pemphigoid includes medical history, physical examination, and clinical symptoms, including affected area and number of blisters per day. Direct and Indirect Immunofluorescence microscopy tests and ELISA are some of the most common diagnostic techniques. Diagnostic delay is quite common as the usual delay is ~6 months.

Bullous Pemphigoid Epidemiology Perspective by DelveInsight

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by Diagnosed Prevalent Cases of Bullous Pemphigoid, Gender-specific Diagnosed Prevalent Cases of Bullous Pemphigoid, Age-specific Diagnosed Prevalent Cases of Bullous Pemphigoid, and Severity-specific Diagnosed Prevalent Cases of Bullous Pemphigoid scenario in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2018 to 2030.

Bullous Pemphigoid Detailed Epidemiology Segmentation

  • In 2020, the total diagnosed prevalent cases of bullous pemphigoid in the 7MM were 124,517 which is likely to increase by 2030 at a CAGR of 0.96% for the study period (2018–2030).
  • In 2020, there were 25,041 diagnosed prevalent cases of bullous pemphigoid in the United States, these cases are expected to increase at a CAGR of 1.26% for the study period of 2018–2030.
  • Assessments as per DelveInsight's analysts showed that there were 13,772 cases of the mild-moderate form of bullous pemphigoid and 11,268 cases of the severe form of bullous pemphigoid in the United States in 2020.
  • Assessments as per DelveInsight analysts showed that 47% of total cases of bullous pemphigoid in the United States in 2020 were from the age group above 80 years.
  • In 2020, males and females contributed to 44% and 56% of the total diagnosed prevalent cases of Bullous Pemphigoid in the United States, respectively.
  • Among the European countries, the UK had the highest diagnosed prevalent population of bullous pemphigoid with 24,644 cases, followed by France which had 23,843 diagnosed prevalent cases in 2020. On the other hand, Spain had the lowest diagnosed prevalent population of 10,920 in 2020.
  • In 2020, Japan accounted for 8,619 diagnosed prevalent cases of bullous pemphigoid which is the least cases among 7MM countries.

Scope of the Report

  • The report covers the descriptive overview of bullous pemphigoid, explaining its causes, signs, and symptoms, and pathophysiology.
  • The report provides insight into the 7MM historical and forecasted patient population covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
  • The report assesses the disease risk and burden.
  • The report provides the segmentation of the disease epidemiology for 7MM by segmented by diagnosed prevalent cases of bullous pemphigoid, gender-specific diagnosed prevalent cases of bullous pemphigoid, age-specific diagnosed prevalent cases of bullous pemphigoid, and severity-specific diagnosed prevalent cases of bullous pemphigoid.

Report Highlights

  • 10-Year Forecast of Bullous Pemphigoid
  • 7MM Coverage
  • Diagnosed Prevalent Cases of Bullous Pemphigoid
  • Gender-specific Diagnosed Prevalent Cases of Bullous Pemphigoid
  • Age-specific Diagnosed Prevalent Cases of Bullous Pemphigoid
  • Severity-specific Diagnosed Prevalent Cases of Bullous Pemphigoid

Key Questions Answered

  • What are the disease risk, burdens, and unmet needs of Bullous Pemphigoid?
  • What is the historical Bullous Pemphigoid patient population in the United States, EU5 (Germany, France, Italy, Spain, and the UK), and Japan?
  • What would be the forecasted patient population of Bullous Pemphigoid at the 7MM level?
  • What will be the growth opportunities across the 7MM with respect to the patient population pertaining to Bullous Pemphigoid?
  • Out of the countries mentioned above, which country would have the highest patient population of Bullous Pemphigoid during the forecast period (2021–2030)?
  • At what CAGR the population is expected to grow across the 7MM during the forecast period (2021–2030)?

Reasons to buy

The Bullous Pemphigoid report will allow the user to -

  • Develop business strategies by understanding the trends shaping and driving the 7MM Bullous Pemphigoid Epidemiology.
  • The Bullous Pemphigoid epidemiology report and model were written and developed by Masters and PhD level epidemiologists.
  • The Bullous Pemphigoid epidemiology model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based on transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over the 10-year forecast period using reputable sources.

Key Assessments

  • Patient Segmentation
  • Disease Risk and Burden
  • Risk of disease by the segmentation
  • Factors driving growth in a specific patient population

1. Key Insights

2. Report Introduction

3. Bullous Pemphigoid Epidemiology Overview at a Glance

3.1. Epidemiology Share (%) Distribution of Bullous Pemphigoid in 2018

3.2. Epidemiology Share (%) Distribution of Bullous Pemphigoid in 2030

4. Executive Summary of Bullous Pemphigoid

5. Disease Background and Overview

5.1. Introduction

5.2. Types of Bullous Pemphigoid

5.3. Causes

5.4. Symptoms of Bullous Pemphigoid

5.5. Pathogenesis of Bullous Pemphigoid

5.5.1. Neurologic disorders and BP

5.5.2. Malignancies in BP

5.5.3. Thrombotic risk and BP

5.6. Biomarkers of Bullous Pemphigoid

5.6.1. BP-related autoantibodies as biomarkers of BP disease

5.6.2. Inflammation and biomarkers in BP disease

5.6.2.1. Markers of BP activity and severity

5.6.2.2. Markers of BP outcome

5.7. Genetic Analysis

5.8. Diagnosis of Bullous Pemphigoid

5.8.1. History

5.8.2. Clinical manifestation

5.8.3. Histological examination

5.8.4. Direct Immunopathological tests

5.8.5. Indirect immunofluorescence tests

5.8.6. ELISA tests

5.8.7. Differential diagnosis

5.8.8. Diagnostic Algorithm of Bullous Pemphigoid

5.9. Diagnostic Guidelines of Bullous Pemphigoid

5.9.1. Japanese guidelines for the management of Pemphigoid (including epidermolysis bullosa acquisita [EBA])

5.9.1.1. Diagnostic criteria

5.9.1.2. Disease severity determination criteria

6. Epidemiology and Patient Population

6.1. Key Findings

6.2. Methodology of Epidemiology

6.3. Total Diagnosed Prevalent Cases of Bullous Pemphigoid in the 7MM

6.4. Epidemiology of Bullous Pemphigoid

6.5. The United States

6.5.1. Diagnosed Prevalent Cases of Bullous Pemphigoid in the US

6.5.2. Gender-specific Diagnosed Prevalent Cases of Bullous Pemphigoid in the US

6.5.3. Age-specific Diagnosed Prevalent Cases of Bullous Pemphigoid in the US

6.5.4. Severity-specific Diagnosed Prevalent Cases of Bullous Pemphigoid in the US

6.6. EU5

6.6.1. Germany

6.6.1.1. Diagnosed Prevalent Cases of Bullous Pemphigoid in Germany

6.6.1.2. Gender-specific Diagnosed Prevalent Cases of Bullous Pemphigoid in Germany

6.6.1.3. Age-specific Diagnosed Prevalent Cases of Bullous Pemphigoid in Germany

6.6.1.4. Severity-specific Diagnosed Prevalent Cases of Bullous Pemphigoid in Germany

6.6.2. France

6.6.2.1. Diagnosed Prevalent Cases of Bullous Pemphigoid in France

6.6.2.2. Gender-specific Diagnosed Prevalent Cases of Bullous Pemphigoid in France

6.6.2.3. Age-specific Diagnosed Prevalent Cases of Bullous Pemphigoid in France

6.6.2.4. Severity-specific Diagnosed Prevalent Cases of Bullous Pemphigoid in France

6.6.3. Italy

6.6.3.1. Diagnosed Prevalent Cases of Bullous Pemphigoid in Italy

6.6.3.2. Gender-specific Diagnosed Prevalent Cases of Bullous Pemphigoid in Italy

6.6.3.3. Age-specific Diagnosed Prevalent Cases of Bullous Pemphigoid in Italy

6.6.3.4. Severity-specific Diagnosed Prevalent Cases of Bullous Pemphigoid in Italy

6.6.4. Spain

6.6.4.1. Diagnosed Prevalent Cases of Bullous Pemphigoid in Spain

6.6.4.2. Gender-specific Diagnosed Prevalent Cases of Bullous Pemphigoid in Spain

6.6.4.3. Age-specific Diagnosed Prevalent Cases of Bullous Pemphigoid in Spain

6.6.4.4. Severity-specific Diagnosed Prevalent Cases of Bullous Pemphigoid in Spain

6.6.5. The United Kingdom

6.6.5.1. Diagnosed Prevalent Cases of Bullous Pemphigoid in the United Kingdom

6.6.5.2. Gender-specific Diagnosed Prevalent Cases of Bullous Pemphigoid in the United Kingdom

6.6.5.3. Age-specific Diagnosed Prevalent Cases of Bullous Pemphigoid in the United Kingdom

6.6.5.4. Severity-specific Diagnosed Prevalent Cases of Bullous Pemphigoid in the United Kingdom

6.7. Japan

6.7.1. Diagnosed Prevalent Cases of Bullous Pemphigoid in Japan

6.7.2. Gender-specific Diagnosed Prevalent Cases of Bullous Pemphigoid in Japan

6.7.3. Age-specific Diagnosed Prevalent Cases of Bullous Pemphigoid in Japan

6.7.4. Severity-specific Diagnosed Prevalent Cases of Bullous Pemphigoid in Japan

7. KOL Views

8. Appendix

8.1. Bibliography

8.2. Report Methodology

9. DelveInsight Capabilities

10. Disclaimer

11. About DelveInsight

List of Table

Table 1: Summary of Bullous Pemphigoid Epidemiology and Key Events (2018–2030)

Table 2: Types of Bullous pemphigoid

Table 3: Bullous Pemphigoid-related inflammation biomarkers

Table 4: Summary of targeted antigens, produced antibodies, and associated genetics of common pemphigus and pemphigoid disease

Table 5: Diagnostic criteria for pemphigoid (including epidermolysis bullosa acquisita)

Table 6: Disease severity determination criteria for pemphigoid (including epidermolysis bullosa acquisita)

Table 7: Total Diagnosed Prevalent Cases of Bullous Pemphigoid in the 7MM (2018–2030)

Table 8: Diagnosed Prevalent Cases of Bullous Pemphigoid in the United States (2018–2030)

Table 9: Gender-specific Diagnosed Prevalent Cases of BP in the United States (2018–2030)

Table 10: Age-specific Diagnosed Prevalent Cases of Bullous Pemphigoid in the United States (2018–2030)

Table 11: Severity-specific Diagnosed Prevalent Cases of Bullous Pemphigoid in the United States (2018–2030)

Table 12: Diagnosed Prevalent Cases of Bullous Pemphigoid in Germany (2018–2030)

Table 13: Gender-specific Diagnosed Prevalent Cases of Bullous Pemphigoid in Germany (2018–2030)

Table 14: Age-specific Diagnosed Prevalent Cases of Bullous Pemphigoid in Germany (2018–2030)

Table 15: Severity-specific Diagnosed Prevalent Cases of Bullous Pemphigoid in Germany (2018–2030)

Table 16: Diagnosed Prevalent Cases of Bullous Pemphigoid in France (2018–2030)

Table 17: Gender-specific Diagnosed Prevalent Cases of Bullous Pemphigoid in France (2018–2030)

Table 18: Age-specific Diagnosed Prevalent Cases of Bullous Pemphigoid in France (2018–2030)

Table 19: Severity-specific Diagnosed Prevalent Cases of Bullous Pemphigoid in France (2018–2030)

Table 20: Diagnosed Prevalent Cases of Bullous Pemphigoid in Italy (2018–2030)

Table 21: Gender-specific Diagnosed Prevalent Cases of Bullous Pemphigoid in Italy (2018–2030)

Table 22: Age-specific Diagnosed Prevalent Cases of Bullous Pemphigoid in Italy (2018–2030)

Table 23: Severity-specific Diagnosed Prevalent Cases of Bullous Pemphigoid in Italy (2018–2030)

Table 24: Diagnosed Prevalent Cases of Bullous Pemphigoid in Spain (2018–2030)

Table 25: Gender-specific Diagnosed Prevalent Cases of Bullous Pemphigoid in Spain (2018–2030)

Table 26: Age-specific Diagnosed Prevalent Cases of Bullous Pemphigoid in Spain (2018–2030)

Table 27: Severity-specific Diagnosed Prevalent Cases of Bullous Pemphigoid in Spain (2018–2030)

Table 28: Diagnosed Prevalent Cases of Bullous Pemphigoid in the United Kingdom (2018–2030)

Table 29: Gender-specific Diagnosed Prevalent Cases of Bullous Pemphigoid in the United Kingdom (2018–2030)

Table 30: Age-specific Diagnosed Prevalent Cases of Bullous Pemphigoid in the United Kingdom (2018–2030)

Table 31: Severity-specific Diagnosed Prevalent Cases of Bullous Pemphigoid in the United Kingdom (2018–2030)

Table 32: Diagnosed Prevalent Cases of Bullous Pemphigoid in Japan (2018–2030)

Table 33: Gender-specific Diagnosed Prevalent Cases of Bullous Pemphigoid in Japan (2018–2030)

Table 34: Age-specific Diagnosed Prevalent Cases of Bullous Pemphigoid in Japan (2018–2030)

Table 35: Severity-specific Diagnosed Prevalent Cases of Bullous Pemphigoid in Japan (2018–2030)

List of Figures

Figure 1: Bullous Pemphigoid

Figure 2: Causes of Bullous Pemphigoid

Figure 3: Symptoms of Bullous pemphigoid

Figure 4: Pathogenesis of Bullous Pemphigoid

Figure 5: Diagnostic Approach to the Patient with Bullous Pemphigoid

Figure 6: Diagnostic algorithm of Bullous Pemphigoid

Figure 7: Total Diagnosed Prevalent Cases of Bullous Pemphigoid in the 7MM (2018–2030)

Figure 8: Diagnosed Prevalent Cases of Bullous Pemphigoid in the United States (2018–2030)

Figure 9: Gender-specific Diagnosed Prevalent Cases of BP in the United States (2018–2030)

Figure 10: Age-specific Diagnosed Prevalent Cases of BP in the United States (2018–2030)

Figure 11: Severity-specific Diagnosed Prevalent Cases of Bullous Pemphigoid in the United States (2018–2030)

Figure 12: Diagnosed Prevalent Cases of Bullous Pemphigoid in Germany (2018–2030)

Figure 13: Gender-specific Diagnosed Prevalent Cases of Bullous Pemphigoid in Germany (2018–2030)

Figure 14: Age-specific Diagnosed Prevalent Cases of Bullous Pemphigoid in Germany (2018–2030)

Figure 15: Severity-specific Diagnosed Prevalent Cases of Bullous Pemphigoid in Germany (2018–2030)

Figure 16: Diagnosed Prevalent Cases of Bullous Pemphigoid in France (2018–2030)

Figure 17: Gender-specific Diagnosed Prevalent Cases of Bullous Pemphigoid in France (2018–2030)

Figure 18: Age-specific Diagnosed Prevalent Cases of Bullous Pemphigoid in France (2018–2030)

Figure 19: Severity-specific Diagnosed Prevalent Cases of Bullous Pemphigoid in France (2018–2030)

Figure 20: Diagnosed Prevalent Cases of Bullous Pemphigoid in Italy (2018–2030)

Figure 21: Gender-specific Diagnosed Prevalent Cases of Bullous Pemphigoid in Italy (2018–2030)

Figure 22: Age-specific Diagnosed Prevalent Cases of Bullous Pemphigoid in Italy (2018–2030)

Figure 23: Severity-specific Diagnosed Prevalent Cases of Bullous Pemphigoid in Italy (2018–2030)

Figure 24: Diagnosed Prevalent Cases of Bullous Pemphigoid in Spain (2018–2030)

Figure 25: Gender-specific Diagnosed Prevalent Cases of Bullous Pemphigoid in Spain (2018–2030)

Figure 26: Age-specific Diagnosed Prevalent Cases of Bullous Pemphigoid in Spain (2018–2030)

Figure 27: Severity-specific Diagnosed Prevalent Cases of Bullous Pemphigoid in Spain (2018–2030)

Figure 28: Diagnosed Prevalent Cases of Bullous Pemphigoid in the United Kingdom (2018–2030)

Figure 29: Gender-specific Diagnosed Prevalent Cases of Bullous Pemphigoid in the United Kingdom (2018–2030)

Figure 30: Age-specific Diagnosed Prevalent Cases of Bullous Pemphigoid in the United Kingdom (2018–2030)

Figure 31: Severity-specific Diagnosed Prevalent Cases of Bullous Pemphigoid in the United Kingdom (2018–2030)

Figure 32: Diagnosed Prevalent Cases of Bullous Pemphigoid in Japan (2018–2030)

Figure 33: Gender-specific Diagnosed Prevalent Cases of Bullous Pemphigoid in Japan (2018–2030)

Figure 34: Age-specific Diagnosed Prevalent Cases of Bullous Pemphigoid in Japan (2018–2030)

Figure 35: Severity-specific Diagnosed Prevalent Cases of Bullous Pemphigoid in Japan (2018–2030)

Forward to Friend

Need A Quote